Opdivo trial stopped early as BMS med tops Afinitor in kidney cancer

Bristol-Myers Squibb ($BMY) hit a big milestone in its quest to expand use of the immunotherapy Opdivo in a slate of cancer types. In a late-stage kidney cancer study, Opdivo showed a survival advantage over Novartis' ($NVS) Afinitor, prompting a monitoring committee to stop the trial early. Release

Suggested Articles

Dupixent has been posting strong sales growth for Sanofi, and now the drugmaker has a third FDA indication to keep the momentum going.

Acadia Pharmaceuticals is taking Parkinson’s disease education on the road in a partnership with the Michael J. Fox Foundation.

AbbVie continues its long-running aggressive TV ad push for Humira last month, while Gilead Sciences takes two spots in the top 10 tally from iSpot.